AstraZeneca weighing bid for Mereo BioPharma: report

AstraZeneca /zigman2/quotes/200304487/composite AZN -0.70% /zigman2/quotes/203048482/delayed UK:AZN +1.02% is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma /zigman2/quotes/205704941/composite MREO +1.01% , The Times reported without attribution . AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist's partners, which include Novartis /zigman2/quotes/203243705/composite NVS -0.39% , OncXerna and Ultragenyx /zigman2/quotes/204970392/composite RARE -0.95% .

/zigman2/quotes/200304487/composite

Add to watchlist AZN

AstraZeneca PLC ADR

US : U.S.: Nasdaq

$ 65.53

-0.46 -0.70%

Volume: 3.18M

Jan. 27, 2023 4:00p

P/E Ratio

100.38

Dividend Yield

2.17%

Market Cap

$203.43 billion

Rev. per Employee

$544,657

/zigman2/quotes/203048482/delayed

Add to watchlist UK:AZN

AstraZeneca PLC

UK : U.K.: London

10,730.00 p

+108.00 +1.02%

Volume: 389,284

Jan. 30, 2023 1:36p

P/E Ratio

97.83

Dividend Yield

2.07%

Market Cap

£164.62 billion

Rev. per Employee

£426,154

/zigman2/quotes/205704941/composite

Add to watchlist MREO

Mereo BioPharma Group PLC ADR

US : U.S.: Nasdaq

$ 1.00

+0.01 +1.01%

Volume: 278,246

Jan. 27, 2023 4:00p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$124.99 million

Rev. per Employee

N/A

/zigman2/quotes/203243705/composite

Add to watchlist NVS

Novartis AG ADR

US : U.S.: NYSE

$ 89.49

-0.35 -0.39%

Volume: 1.70M

Jan. 27, 2023 4:00p

P/E Ratio

9.21

Dividend Yield

2.41%

Market Cap

$196.24 billion

Rev. per Employee

$489,671

/zigman2/quotes/204970392/composite

Add to watchlist RARE

Ultragenyx Pharmaceutical Inc.

US : U.S.: Nasdaq

$ 43.72

-0.42 -0.95%

Volume: 449,661

Jan. 27, 2023 4:00p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$3.07 billion

Rev. per Employee

$306,854